Usage Examples
- We are filing the 351(k) without an interchangeability claim and adding it by supplement once the switching data reads out.
- Payer contracting assumes interchangeability, so the switching package is on the critical path, not the nice-to-have list.
- First-interchangeable exclusivity blocks our interchangeability determination, not our biosimilar approval.
What is Biosimilar Interchangeability?
Biosimilar interchangeability is a statutory FDA determination, one tier above biosimilarity, that a biosimilar produces the same clinical result as its reference product in any given patient and may be substituted without the prescriber's intervention.
Biosimilar interchangeability exists because biosimilarity alone does not authorize a pharmacist to swap products. Congress wrote a second, higher determination into the Public Health Service Act so a biosimilar could reach patients through ordinary pharmacy substitution rather than requiring every prescriber to write for it by name. Without it, biosimilar uptake depends entirely on physician-by-physician conversion.
Biosimilar interchangeability covers two showings beyond biosimilarity: that the product can be expected to produce the same clinical result as the reference product in any given patient, and, for products administered more than once, that alternating or switching carries no greater risk than staying on the reference product. It does not cover comparative superiority, new indications, or the act of dispensing, which state pharmacy law governs.
Biosimilar interchangeability is claimed either in the original 351(k) application or in a supplement, which lets sponsors separate approval timing from the switching data package. The first product to earn the determination against a given reference product triggers an exclusivity window during which FDA will not make a later interchangeability approval effective, so filing order carries direct commercial value.
Not to be confused with
- Biosimilar
- biosimilarity is the base determination; interchangeability is a separate finding layered on top of it. Every interchangeable product is a biosimilar, but the reverse does not hold, and the two words are not equivalent in a label or a payer contract.
- Generic drug
- a generic is a chemically identical small molecule rated therapeutically equivalent under the Orange Book. An interchangeable biosimilar is not identical to its reference product; it clears a switching standard, not a sameness standard.
- Automatic substitution
- the federal determination only establishes that the product may be substituted without the prescriber's intervention. Whether a given pharmacy actually substitutes, and what it must tell the prescriber, is set by state pharmacy practice law.
- Therapeutic equivalence (AB rating)
- an Orange Book construct for drugs approved under the FD&C Act. Biologics are licensed under the PHS Act and listed in the Purple Book, so there is no AB rating for a biosimilar to earn.
The interchangeability standard is statutory. These are the showings an application or supplement has to support.
What you must do
- 1Establish biosimilarity to the reference product first, because interchangeability is determined on top of that finding rather than instead of itPHS Act 351(k)(4)(A)
- 2Show the product can be expected to produce the same clinical result as the reference product in any given patientPHS Act 351(k)(4)(A)
- 3For a product administered more than once, show that alternating or switching between it and the reference product is no riskier, in safety or diminished efficacy, than using the reference product without the switchPHS Act 351(k)(4)(B)
- 4Submit the showing in the 351(k) application or in a supplement to it, since FDA makes the determination on eitherPHS Act 351(k)(4)
- 5Word the substitution claim in the statutory terms, namely substitutable for the reference product without the intervention of the prescribing health care providerPHS Act 351(i)(3)
- 6Clear first-interchangeable exclusivity for the reference product before committing to a launch date, because FDA cannot make a later interchangeability approval effective until it runsPHS Act 351(k)(6)
Common mistakes
Calling a biosimilar "interchangeable" before FDA has determined it
interchangeability is a determination the agency makes under the statute, not a description of how similar the molecule is. Using the word without the determination is a claim FDA has not made, and it does not survive promotional review or a payer's diligence.
Assuming interchangeability forces pharmacy substitution
the federal determination removes the need for prescriber intervention and nothing more. Dispensing rules, notification duties, and record-keeping sit in state law, so uptake models built on the FDA designation alone overstate conversion.
Ignoring first-interchangeable exclusivity when sequencing the filing
a competitor's earlier determination against the same reference product can stop FDA from making your interchangeability approval effective, even though your biosimilar approval is untouched. Teams usually discover this after the switching study is already sunk cost.
When This Matters
- We are filing the 351(k) without an interchangeability claim and adding it by supplement once the switching data reads out.
- Payer contracting assumes interchangeability, so the switching package is on the critical path, not the nice-to-have list.
- First-interchangeable exclusivity blocks our interchangeability determination, not our biosimilar approval.
Frequently Asked Questions
Interchangeability is an additional determination on top of biosimilarity. A biosimilar is highly similar to its reference product; an interchangeable biosimilar must also be expected to produce the same clinical result in any given patient, and for repeat-dose products, show that alternating with the reference product adds no safety or efficacy risk.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
